jounce.png
Jounce Therapeutics Reports First Quarter 2021 Financial Results
04 mai 2021 06h30 HE | Jounce Therapeutics, Inc.
- Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab - - Ended the...
jounce.png
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
28 avr. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tuesday, May 4, 2021
27 avr. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
12 avr. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
10 avr. 2021 08h31 HE | Jounce Therapeutics, Inc.
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature- - JTX-8064’s mechanism of...
jounce.png
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
12 mars 2021 11h10 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting
10 mars 2021 16h30 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
09 mars 2021 22h17 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Announces Proposed Offering of Common Stock
09 mars 2021 16h01 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
25 févr. 2021 06h30 HE | Jounce Therapeutics, Inc.
- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 - - Ended 2020 with $213.2 million in...